News
The most recent news and industry headlines are presented in this section. Our dedicated team closely observes the pharmaceutical industry and keeps you informed of the most recent developments around the Europe.
ERS Genomics and Medicines Discovery Catapult Sign CRISPR/Cas9 License Agreement
Wednesday, September 04, 2024ERS Genomics Limited ERS the CRISPR licensing Company and Medicines Discovery Catapult MDC an independent notforprofit drug discovery innovation centre have signed a nonexclusive commercialuse CRISPR license agreement
Prilenia’s Pridopidine for Huntington’s Disease Accepted for European Marketing Authorisation Review
Wednesday, September 04, 2024Prilenia Therapeutics BV a clinical stage biotechnology company focused on the urgent mission to develop novel therapeutics to slow the progression of neurodegenerative diseases and neurodevelopmental disorders announces the acceptance of its Europea...
Soligenix Receives European Patent for Improved Production of Synthetic Hypericin
Tuesday, September 03, 2024Soligenix Inc a latestage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need announced today that the European Patent Office has granted the patent entitled
Skyline Therapeutics' Novel Gene Therapy SKG1108 Receives FDA Orphan Drug Designation for Retinitis Pigmentosa
Tuesday, September 03, 2024Skyline Therapeutics an innovationdriven gene therapy company committed to developing unique and novel solutions for rare and severe diseases announced that the US Food and Drug Administration FDA has granted Orphan Drug Designation ODD for SKG
George Medicines demonstrates potential of novel, low-dose, triple combination pill to transform management of hypertension in Hot Line Session at ESC Congress 2024
Monday, September 02, 2024George Medicines a latestage biopharmaceutical company addressing significant unmet need in the treatment of cardiometabolic disease today announced the presentation of results from its two pivotal Phase III trials at a Hot Line session of the Europe...
BridgeBio Shares Data on Serum TTR Increase When Switching Participants from Placebo and Tafamidis to Acoramidis in ATTRibute-CM and its Open-Label Extension
Monday, September 02, 2024BridgeBio Pharma Inc a commercialstage biopharmaceutical company focused on genetic diseases presented additional data from an analysis of its Phase ATTRibuteCM and openlabel extension study of acoramidis in ATTRCM at the European Society of Cardiol...
Sanyou Bio Launches Comprehensive Monkeypox Product Line
Saturday, August 31, 2024Sanyou Biopharmaceuticals Shanghai Co Ltd announced the launch of a comprehensive product line targeting monkeypox which includes antigens monoclonal antibodies and overexpression cell lines This product line features items across three main categor...
Adaptive Announces IVDR Certification for clonoSEQ® in the European Union
Friday, August 30, 2024Adaptive Biotechnologies Corporation a commercialstage biotechnology company focused on translating the genetics of the adaptive immune system into clinical products for diagnosing and treating diseases today announced that its clonoSEQ
SciSparc and Clearmind Medicine Collaboration Results in Publication of Application for Innovative Ketamine-Based Combination
Friday, August 30, 2024SciSparc Ltd a clinicalstage specialty pharmaceutical company focused on developing therapies for central nervous system disorders and rare diseases announced today that its ongoing collaboration with Clearmind Medicine Inc
QIAGEN extends QIAstat-Dx's reach into precision medicine with a new partnership for companion diagnostics in chronic diseases
Thursday, August 29, 2024QIAGEN has announced the expansion of its Master Collaboration Agreement with AstraZeneca to develop and commercialize companion diagnostics CDx for AstraZenecas upcoming therapies targeting chronic diseases
